Current Concepts in the Prevention of Alzheimer's Disease

CNS Spectrums

Volumn 8, Issue 11, 2003, Pages 846-853

  Sano, Mary ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; CELECOXIB; CONJUGATED ESTROGEN; CYCLOOXYGENASE 2 INHIBITOR; FLAVANOID; GINKGO BILOBA EXTRACT; IBUPROFEN; INDOMETACIN; MEDROXYPROGESTERONE ACETATE; NAPROXEN; PRAVASTATIN; SELEGILINE; SELENIUM; SIMVASTATIN; TOCOPHEROL;

AGING; ALZHEIMER DISEASE; CLINICAL TRIAL; DEMENTIA; ELDERLY CARE; HEART DISEASE; HUMAN; INCIDENCE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; META ANALYSIS; POPULATION RISK; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SAFETY; SECONDARY PREVENTION; ADULT; AGED; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; FEMALE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; COMORBIDITY; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS;

EID: 1542647457     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900019283     Document Type: Review

References (57)

1. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88:1337-1342.
2. Torian L, Davidson E, Fulop G, Sell L, Fillit H. The effect of dementia on acute care in a geriatric medical unit. Int Psychogeriatr. 1992;4:231-239.
3. Kirschstein R. Disease-specific estimates of direct and indirect costs of illness and NIH support. National Institutes of Health Web site. Available at: http://www1.od.nih.gov/osp/ospp/ecostudies/COIreportweb.htm. Accessed June 11, 2002.
4. McDaid D. Estimating the cost of informal care for people with Alzheimer's disease: methodological and practical challenges. Int J Geriatr Psychiatry. 2001;16:400-405.
5. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci. 2002;25:22-26.
6. Wenk GL, McGann K, Mencarelli A, Hauss-Wegrzyniak B, Del Soldato P, Fiorucci S. Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons. Eur J Pharmacol. 2000;402:77-85
7. Sano M. Prevention of Alzheimer's disease: the problem of the drugs and the designs. Curr Neurol Neurosci Rep. 2002;2:392-399.
8. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-1222.
9. Marder K, Sano M. Estrogen to treat Alzheimer's disease: too little, too late? So what's a woman to do? Neurology. 2000;54:2035-2037.
10. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer's disease progression: a randomized controlled trial. JAMA. 2003;289:2819-2826.
11. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. A review. Free Radic Res. 2002;36:1307-1313.
12. Morris MC, Evans DA, Bienias JL, et al. Dietary intake of antioxidant nutrients and the risk of incident Alzheimer's disease in a biracial community study. JAMA. 2002;287:3230-3237.
13. Engelhart MJ, Geerlings MI, Ruitenberg A, et al. Dietary intake of anti-oxidants and risk of Alzheimer's disease. JAMA. 2002;287:3223-3229.
14. Sano M. Do dietary anti-oxidants prevent Alzheimer's disease. Lancet Neurol. 2002;1:343.
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23-33.
16. Kieburtz K, McDermott M, Como P, et al. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group. Neurology. 1994;44:1756-1759.
17. Prevention of Alzheimer's Disease by Vitamin E and Selenium (PREADVISE). Available at: Clinicaltrials.gov/ct/show/ NCT000040378. Accessed September 6, 2003.
18. Scholtyssek H, Damerau W, Wessel R, Schimke I. Antioxidative activity of ginkgolides against superoxide in an aprotic environment. Chem Biol Interact. 1997;106:83-90.
19. Barkats M, Venault P, Christen Y, Cohen-Salmon C. Effect of long-term treatment with EGb 761 on age-dependent structural changes in the hippocampi of three inbred mouse strains. Life Sciences. 1995;56:213-222.
20. van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG. The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc. 2000;48:1183-1194.
21. Ginkgo Biloba Prevention Trial in Older Individuals, RFA: AT-99-001, National Center for Complementary and Alternative Medicine and National Institute on Aging, February 26, 1999.
22. Perenboom RJ, Boshuizen HC, Breteler MM, Ott A, Van de Water HP. Dementia-free life expectancy (DemFLE) in The Netherlands. Soc Sci Med. 1996;43:1703-1707.
23. Toran-Allerand CD, Miranda RC, Bentham WD, et al. Estrogen receptors colocalize with low-affinity nerve growth factor receptors in cholinergic neurons of the basal forebrain. Proc Natl Acad Sci U S A. 1992;89:4668-4672.
24. Gould E, Woolly CS, Frankfurt M, McEwen BS. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J Neurosci. 1990;10:286-1291.
25. Xu H, Sweeney D, Wang R, et al. Generation of Alzheimer's beta-amyloid protein in the trans-Golgi network in the apparent absence of vesicle formation. Proc Natl Acad Sci U S A. 1997;94:3748-3752.
26. Petanceska SS, Nagy V, Frail D, Gandy S. Ovariectomy and 17 beta-estradiol modulate the levels of Alzheimer's amyloid beta peptides in brain. Exp Gerontol. 2000;35:1317-1325.
27. Yaffe K, Sawaya G, Lieberburg I, Grady D. Estrogen therapy in postmenopausal women: effects on cognitive function and dementia. JAMA. 1998;279:688-695.
28. LeBlanc ES, Janowsky J, Chan BK, Nelson HD. Hormone replacement therapy and cognition: systematic review and meta-analysis. JAMA. 2001;285:1489-1499.
29. Wang PN, Liao SQ, Liu RS, et al. Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study. Neurology. 2000;54:2061-2066
30. Henderson VW, Paganini-Hill A, Miller BL, et al. Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial. Neruology. 2000;54:295-301.
31. Mulnard R, Cotman CW, Kawas C, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA. 2000;283:1007-1015.
32. Grady D, Yaffe K, Kristof M, Lin F, Richards C, Barrett-Connor E. Effect of postmenopausal hormone therapy on cognitive function: the Heart and Estrogen/progestin Replacement Study. Am J Med. 2002;113:543-548.
33. Shumaker SA, Legault C, Thal L, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2651-2662.
34. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289:2663-2672.
35. Aisen PS, Davis KL. Inflammatory mechanism in Alzheimer's disease: implications for therapy. Am J Psychiatry. 1994;151:1105-1113.
36. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000;54:588-592.
37. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609-1611.
38. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 1999;53:197-201.
39. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995;45:51-55.
40. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997;48:626-632.
41. in t'Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-1521.
42. Etminan M, Gill S, Samii A. Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ. 2003;327:128.
43. Martin BK, Meinert CL, Breitner JC; ADAPT Research Group. Double placebo design in a prevention trial for Alzheimer's disease. Control Clin Trials. 2002;23:93-99.
44. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212-216.
45. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-1443.
46. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet. 2000;356:1627-1631.
47. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol. 2002;59:223-227.
48. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
49. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623-1630
50. Miller JW, Green R, Ramos MI, et al. Homocysteine and cognitive function in the Sacramento Area Latino Study on Aging. Am J Clin Nutr. 2003;78:441-447.
51. Joosten E, Lesaffre E, Riezler R, et al. Is metabolic evidence for vitamin B-12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J Gerontol A Biol Sci Med Sci. 1997;52:M76-M79.
52. McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer's type. Int J Geriatr Psychiatry. 1998;13:235-239.
53. Lehmann M, Gottfries CG, Regland B. Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement Geriatr Cogn Disord. 1999;10:12-20.
54. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
55. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer's disease. Arch Neurol. 1998;55:1449-1455.
56. Budge M, Johnston C, Hogervorst E, et al. Plasma total homocysteine and cognitive performance in a volunteer elderly population. Ann N Y Acad Sci. 2000;903:407-410.
57. Aisen PS, Egelko S, Andrews H, et al. A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer's disease. Am J Geriatr Psychiatry. 2003;11:246-249.